+
Lupin Partners With SteinCares To Supply Biosimilar in LATAM
ECONOMY & POLICY

Lupin Partners With SteinCares To Supply Biosimilar in LATAM

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.

As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.

Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).

Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”

Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”

This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Next Story
Real Estate

Manglam, Fern Hotels Sign 200+ Key Apart’otel in Jaipur’s Pinkwalk

Manglam Group has signed a 200+ key serviced apart’otel under the Fern Habitat brand in Jaipur, marking a key milestone in its Rs 10 billion hospitality investment strategy. Located within Pinkwalk, Manglam’s flagship mixed-use development in Jagatpura, the project will cater to both short and extended-stay travellers with apartment-style units paired with hotel services. The Fern Habitat Pinkwalk will offer fully serviced accommodations with kitchenettes, daily housekeeping, and on-site dining. The concept blends the independence of apartment living with the comfort of hotel-grade am..

Next Story
Real Estate

Schon Doorways Launches Monsoon-Ready Aluminium Casement Windows

Schon Doorways, a premium player in doors and window solutions, has launched its new range of aluminium casement and sliding windows, designed specifically to endure the Indian monsoon. Engineered with high-performance tempered glass and ultra-slim aluminium profiles, the windows combine aesthetic appeal with monsoon resilience. Available in single and double track options, the windows offer anti-collision strips, flyscreens, and high load-bearing strength—providing protection against heavy rains, strong winds, and pests. Wall thickness ranges from 1.6 mm to 5.00 mm, offering flexibilit..

Next Story
Resources

LG Charts Global HVAC Leadership With AI, Acquisitions and Localisation

LG Electronics has unveiled a strategic roadmap to transform its ES Company into a top-tier global HVAC solutions provider by 2030, targeting KRW 20 trillion in revenue. The plan, announced at LG Sciencepark, South Korea, focuses on expanding B2B industrial sales, advancing AI-based technologies for data centres, and strengthening localised operations across key regions. Central to LG’s roadmap is growth in the fast-expanding data centre cooling segment. With the global chiller market projected to reach USD 12 billion by 2027, LG aims for KRW 1 trillion in sales by 2027. The company has..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?